CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
Trial details
- Registry ID
- NCT03566043
- Phase
- Phase 2, Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)NCT03566043 | RGNX | Phase 2, Phase 3 | Active not recruiting | 2023-11-27Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |